Identification
- Brand Names
- Advanced Eye Relief Redness Instant Relief
- Generic Name
- Polyethylene glycol 300
- DrugBank Accession Number
- DB11161
- Background
Polyethylene glycol 300 (PEG 300) is a water-miscible polyether with an average molecular weight of 300 g/mol. It is a clear viscous liquid at room temperature with non-volatile, stable properties 1. Polyethylene glycols are widely used in biochemistry, structural biology, and medicine in addition to pharmaceutical and chemical industries. They serve as solubilizers, excipients, lubricants, and chemical reagents. Low molecular weight glycols are observed to exhibit antibacterial properties as well. PEG 300 is found in eye drops as a lubricant to temporarily relieve redness, burning and irritation of the eyes.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Macrogol 300
- PEG 300
- PEG-6
Pharmacology
- Indication
Indicated as a lubricant in over-the-counter ophthalmic solutions to temporarily relieve redness, burning and irritation of the eyes.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
PEGs act as nonionic surfactant to decrease surface tension and condition the stratum corneum, thus enhance the diffusion of other molecules or drugs through the skin 1.
- Mechanism of action
Due to their physical properties, PEG acts as a surfactant by coating the eye. It provides lubrication and surface protection in dry eyes.
- Absorption
PEGs can be absorbed by the gastrointestinal tract following oral administration with the fraction absorbed being dependent on the molecular weight of the compound 1. It is likely to display minimal absorption through the intact skin, but may penetrate through injured skin with compromised barrier function 1.
- Volume of distribution
No pharmacokinetic data available.
- Protein binding
No pharmacokinetic data available.
- Metabolism
Proportion of absorbed PEGs may be metabolized to lower oligomers, glycolic acid, hydroxyglycolic acids and the diglycolic acids homologs, carbon dioxide that is exhaled, and to a minor extent, oxalic acid 1.
- Route of elimination
After oral and intravenous exposure, PEGs are excreted mainly unchanged in the urine and faeces 1.
- Half-life
No pharmacokinetic data available.
- Clearance
No pharmacokinetic data available.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Oral LD50 in rat and mouse are 27500 mg/kg and 31000 mg/kg, respectively MSDS. Dermal LD50 is reported to be 20000 mg/kg in rabbit MSDS. PEGs and their derivatives are not known to cause ocular and dermal irritation, and are associated with low acute and chronic toxicities 1.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Advanced Eye Relief/ Redness Instant Relief Polyethylene glycol 300 (2 mg/1mL) + Naphazoline hydrochloride (0.1 mg/1mL) Solution / drops Ophthalmic Bausch & Lomb Incorporated 2010-09-13 Not applicable US 
ALL CLEAR EYE DROPS Polyethylene glycol 300 (0.2 %) + Naphazoline hydrochloride (0.012 %) Solution Ophthalmic BAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED 2003-01-16 Not applicable Singapore 
Lubricant and Redness Reliever Polyethylene glycol 300 (2 mg/1mL) + Naphazoline hydrochloride (0.1 mg/1mL) Solution / drops Ophthalmic TARGET Corporation 2010-09-13 2021-08-31 US Original Redness Reliever Polyethylene glycol 300 (2 mg/1mL) + Naphazoline hydrochloride (0.1 mg/1mL) Solution / drops Ophthalmic Rite Aid 2010-09-13 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5655G9Y8AQ
- CAS number
- 25322-68-3
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Fruijtier-Polloth C: Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology. 2005 Oct 15;214(1-2):1-38. doi: 10.1016/j.tox.2005.06.001. [Article]
- External Links
- MSDS
- Download (47.8 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Ophthalmic 0.012 % Solution / drops Ophthalmic - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) -11 MSDS water solubility Soluble MSDS - Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at January 07, 2021 03:13